ArticleCureus2026
Medication Adherence in Patients With Glaucoma and Determinants of Treatment Adherence: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to assess the level of medication adherence among patients with glaucoma, examine the association between adherence and glaucoma progression, and identify determinants of adherence.
methodsThis hospital-based, observational, cross-sectional study was conducted over 18 months. A total of 77 patients aged >18 years with glaucomatous changes were included. Data collection involved comprehensive ophthalmic examination and administration of the Glaucoma Adherence Study Questionnaire. Statistical analysis was performed using Epi Info version 7 (CDC, Atlanta, GA).
resultsThe mean age was 60.48 ± 13.32 years, with 62.34% males. Based on perimetry results, 24.7% had mild, 40.3% had moderate, and 35.0% had severe glaucoma. Medication adherence was reported as full adherence by 55.8% (43/77) of patients. Significant determinants influencing adherence included glaucoma severity (p = 0.002), education level (p < 0.001), income (p < 0.001), clinician-patient communication (p < 0.001), annual follow-up (p = 0.03), motivation (p < 0.001), memory (p < 0.001), difficulty in drop administration (p = 0.001), and side effects (p < 0.001).
conclusionMedication adherence among glaucoma patients was suboptimal at 55.8%. Multiple modifiable factors influenced adherence, highlighting the need for targeted interventions, including patient education, simplified regimens, and improved clinician-patient communication, to enhance treatment outcomes. CLINICAL SIGNIFICANCE: Glaucoma is a chronic progressive optic neuropathy and a leading cause of irreversible blindness. So the primary goal of treatment is to lower intraocular pressure (IOP), usually through long-term use of topical medication. Poor adherence to prescribed therapy can lead to inadequate IOP control, faster progression of optic nerve damage, visual field deterioration, increased risk of irreversible vision loss and blindness, and greater healthcare costs due to additional treatment and follow-up visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.